Jérémy Lardon

Jérémy Lardon

Auto-generated profile, based on publicly available information

Jérémy Lardon

A Sorbonne Université , UPMC Université Paris 06, UMR_S 1142, LIMICS , Paris , France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JLJérémy Lardon
Jérémy Lardon
RARedhouane Abdellaoui
Redhouane Abdellaoui
FBFlorelle Bellet
Florelle Bellet
HAHadyl Asfari
Hadyl Asfari
JSJulien Souvignet
Julien Souvignet
CBCédric Bousquet
Cédric Bousquet
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

26 July 2018 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
JLJérémy Lardon
Jérémy Lardon
FBFlorelle Bellet
Florelle Bellet
RARim Aboukhamis
Rim Aboukhamis
HAHadyl Asfari
Hadyl Asfari
JSJulien Souvignet
Julien Souvignet
CBCédric Bousquet
Cédric Bousquet
Background: Social media are currently considered as a potential complementary source of knowledge for drug safety surveillance. Our primary objective was to estimate the frequency of adverse drug reactions (ADRs) experienced by Twitter users. Our secondary objective was to determine whether tweets constitute a valuable and informative source of data for pharmacovigilance purposes, despite limitations on character number per tweet. Research design and methods: We selected a list of 33 drugs subject to careful monitoring due to safety concern in France and Europe, and extracted tweets using the streaming API from 30 September 2014 to 5 April 2015. Two pharmacovigilance centers classified these tweets manually as potential ADR case reports. Results: Among 10,534 tweets, 848 (8.05%) implied or mentioned an ADR without meeting the four FDA criteria required for reporting an ADR, and 289 (2.74%) tweets were classified as ‘case reports.’ Among them 20 (7.27%) tweets mentioned an unexpected ADR and 33 (11.42%) tweets mentioned a serious ADR. Conclusions: With the use of dedicated tools, Twitter could become a complementary source of information for pharmacovigilance, despite a major limitation regarding causality assessment of ADRs in individual tweets, which may improve with the new limitation to 280 characters per tweet.

1 January 2015
Verified
Journal Article
Closed access
JLJérémy Lardon
Jérémy Lardon
HAHadyl Asfari
Hadyl Asfari
JSJulien Souvignet
Julien Souvignet
BTBéatrice Trombert-Paviot
Béatrice Trombert-Paviot
CBCédric Bousquet
Cédric Bousquet

1 January 2015
Verified
Journal Article
Closed access
SKSandrine Katsahian
Sandrine Katsahian
EMErica Simond Moreau
Erica Simond Moreau
DLDamien LeProvost
Damien LeProvost
JLJeremy Lardon
Jeremy Lardon
CBCedric Bousquet
Cedric Bousquet
CFCarole Faviez
Carole Faviez

1 January 2014
Verified
Journal Article
Closed access
JSJulien Souvignet
Julien Souvignet
HAHadyl Asfari
Hadyl Asfari
GDGunnar Declerck
Gunnar Declerck
JLJérémy Lardon
Jérémy Lardon
BTBéatrice Trombert-Paviot
Béatrice Trombert-Paviot
CBCédric Bousquet
Cédric Bousquet

1 January 2016
Verified
Journal Article
Closed access
NTNizar Triki
Nizar Triki
CBCédric Bousquet
Cédric Bousquet
JLJeremy Lardon
Jeremy Lardon
HAHadyl Asfari
Hadyl Asfari
RSRadia Spiga
Radia Spiga
BTBéatrice Trombert-Paviot
Béatrice Trombert-Paviot